Progress in therapeutic monoclonal antibodies targeting hepatitis B surface antigen
10.3760/cma.j.cn112309-20201217-00558
- VernacularTitle:治疗性抗乙型肝炎表面抗原单克隆抗体的研究进展
- Author:
Mingxi YUE
1
;
Meifeng NIE
;
Xiaofen HUANG
;
Tianying ZHANG
;
Qinjian ZHAO
Author Information
1. 厦门大学公共卫生学院，分子疫苗学和分子诊断学国家重点实验室，国家传染病诊断试剂与疫苗工程技术研究中心 361102
- Keywords:
Chronic hepatitis B;
Hepatitis B surface antigen;
Therapeutic monoclonal antibodies;
Combination therapy
- From:
Chinese Journal of Microbiology and Immunology
2021;41(10):805-810
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) is often treated with drugs such as interferons and nucleoside (acid)/nucleotide (acid) analogs. While these drugs are effective in controlling the viral loads, they are not able to eliminate hepatitis B virus (HBV) from the body completely. Besides, side effects and drug resistance may by caused by the long-term use of these drugs. Several monoclonal antibodies (McAbs) against HBV, mostly against hepatitis B surface antigen (HBsAg), have been demonstrated with viral neutralization capability and with effective inhibition of HBV replication in relevant animal models. The use of a McAb individually or in combination with another therapy has the potentials to achieve functional cure of CHB. In this review, we summarized the encouraging results from the research and development of anti-HBV McAbs in clinical or pre-clinical development stage, aiming to provide new idea for the treatment of CHB.
